Exane Derivatives’s Interactive Brokers IBKR Stock Holding History

Exane Derivatives’s Portfolio IBKR Stock Details IBKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,184	Closed	-$59.2K	–	921
2021 Q3	$49.6K	Hold	3,184	–	–	0.01%	614
2021 Q2	$51.2K	Buy	+3,184	New	+$55.1K	0.01%	648

Other funds holding IBKR

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BCM

Bares Capital Management Austin, Texas $1.08B AUM 38.13% 1-Year Est. Return

GWM

Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

JFL

Jarislowsky, Fraser Ltd Montreal, Quebec, Canada $18.2B AUM 22.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cantillon Capital Management New York $15.1B AUM 23.54% 1-Year Est. Return

Exane Derivatives's IBKR Position: Q4 2021 in Review

Exane Derivatives sold out of Interactive Brokers (IBKR) in Q4 2021, closing a stake of 3,184 shares — an estimated $59.2K sold.

Exane Derivatives first reported a position in IBKR in Q2 2021 and held it in 2 quarters. The position peaked at $51.2K in Q2 2021. 339 funds tracked by Wall St. Rank hold IBKR as of Q4 2021.

Exane Derivatives reported no remaining Interactive Brokers position as of Q4 2021 after selling out during the quarter.
Exane Derivatives sold 3,184 Interactive Brokers shares in Q4 2021, an estimated $59.2K.
Exane Derivatives first reported a position in Interactive Brokers in Q2 2021 and held it in 2 quarters.
Exane Derivatives's Interactive Brokers position peaked at $51.2K in Q2 2021.
339 funds tracked by Wall St. Rank held Interactive Brokers as of Q4 2021.

Based on Exane Derivatives's 13F filing for Q4 2021, filed 28 Jan 2022.